Pcn336 - Treatment of Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With Docetaxel in Portugal

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.418
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Indirect Treatment Comparison of Cabazitaxel for Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Been Previously Treated With a Docetaxel-Containing Regimen

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Docetaxel Rechallenge in Patients With Castration-Resistant Prostate Cancer — A Review

European Oncology and Haematology
OncologyHematology
2012English

Case Report: Responses to Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer After Extensive Docetaxel Treatment

Clinical Genitourinary Cancer
OncologyUrology
2011English

Treatment Sequences, Patient Characteristics, and Overall Survival of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer in the Community Setting

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Phase I Trial With a Combination of Docetaxel and 153Sm-Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2011English

Outcome of Combination Chemotherapy With Docetaxel, Estramustine Phosphate, and Carboplatin After Docetaxel and Prednisolone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Journal of Cancer Therapy
2016English

Clinical Study of Long-Term Docetaxel Based Chemotherapy Treatment for Patients With Castration-Resistant Prostate Cancer

Japanese Journal of Urology
Urology
2014English

Prognostic Value of 18f-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Docetaxel

Contrast Media and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2019English

Guideline Adherence in Docetaxel Treatment of Castration Resistant Prostate Cancer (CRPC) Patients in a Real-World Population: The Castration Resistant Prostate Cancer Registry (CAPRI) in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy